AKT1 and malignant glioma: We, among others, have shown that many malignant gliomas are also TRAIL resistant, despite expression of TRAIL receptors (17–19) and aberrance in the NF-κB, protein kinase C, Bcl-2 and Akt pathways have all been implicated in TRAIL resistance in glioma (19–21).